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Background: Ovarian cancer is the most deadly gynecological cancer because of late diagnosis, frequently with
diffuse peritoneal metastases. Recent findings have shown that serous epithelial ovarian cancer has a narrow
mutational spectrum with TP53 being the most frequently targeted when single genes are considered. It is,
however, important to understand which pathways as a whole may be targeted for mutation.
Findings: Previously published mutational data provided by the cancer genome atlas networks findings on ovarian
cancer was searched for statistically significant enrichment of genes in pathways. These pathways were then
searched in all patients to identify the spectrum of mutations. Statistical significance was further shown through
in-silico permutations of exome sequences using empirically observed mutation rates. We detected mutations in
the cell adhesion pathway genes in more than 89% of serous epithelial ovarian cancer patients. This level of near
universal mutational targeting of the cell adhesion pathway, including the extracellular matrix pathway, is previously
unreported in epithelial ovarian cancer.
Conclusions: Taken together with previous studies on the role of cell adhesion and extracellular matrix gene
expression in ovarian cancer and metastasis, our results identify pathways for which the mutational prevalence has
previously been overlooked using single gene approaches. Analysis of mutations at the pathway level will be critical
in studying heterogeneous diseases such as ovarian cancer.Background
Epithelial Ovarian Carcinoma (EOC) is the sixth most
common malignancy in women [1] and has a poor over-
all survival rate (20 to 30% at 5 years). High-grade serous
carcinoma is the most frequent type of ovarian cancer.
The poor survival rate is due mainly to a large tumor
burden and frequent, extensive peritoneal metastatic
lesions at diagnosis. This results in difficulty to achieve
complete optimal resection, despite advances in surgical
practice. Indeed the importance of the metastatic
process in ovarian cancer has been clearly demonstrated
in the clinical setting by the fact that peritoneal residual
disease at the end of the surgical treatment (even below
5 mm) impacts prognosis [2,3].* Correspondence: jom2042@qatar-med.cornell.edu
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reproduction in any medium, provided the orDespite initial chemosensitivity and ultra-radical
debulking surgery most patients will present with diffuse
peritoneal recurrences rather than distant metastasis.
Therefore, understanding the molecular mechanisms of
progression from primary to metastases is critical for the
development of effective therapies. Most studies of EOC
have focused on the primary tumor including mutational
and gene expression analysis. Many transcriptomic stud-
ies have been performed demonstrating different gene
expression signatures depending on the histologic sub-
types, the grade and stage [4-6]. Others have defined
several prognosis signatures however there is only little
overlap between these studies [7-9].
Recent results from the TCGA group’s exome sequen-
cing of 316 epithelial ovarian cancer primary tumors
with matched controls revealed a very narrow spectrum
for somatic mutations in EOC. Specifically, TP53 was
mutated in approximately 96% of EOC primary tumors.
The next most frequently affected genes were mutated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TP53 mutations suggests an early and central role of
TP53 mutations in EOC.
In our recent studies of copy number variations and
gene expression differences between primary and meta-
static lesions [10,11] we observed clear targeting of path-
ways, rather than specific genes in EOC. Indeed our
findings showed that analysis of pathways reduced the
overall heterogeneity in comparisons and this pathway-
based approach may also be important in studying the
mutational spectrum of ovarian cancer as well. The im-
portance of pathway-based analysis over single gene ana-
lysis is due to the fact that similar downstream effects
can be obtained by mutation of different genes within
the same pathway. The TCGA study included some
discovery-based pathway analysis on copy number and
gene expression data using the PARADIGM approach.
Analysis of mutations, however, was mainly restricted to
certain known cancer pathways. The HOTNET approach
overlaid the mutational data on protein interaction net-
works but no further discovery-based pathway analyses
of gene mutations were reported [12].
We therefore hypothesized that analyzing the recent
mutational data in EOC [12] using a broader functional
pathway approach such as the Gene Ontologies or
KEGG could reveal consistent targeting of pathways
other than known cancer pathways, and could reduce
the observed heterogeneity when only individual genes
are considered. Furthermore, analysis of low frequency
mutated genes within frequently mutated pathways, may
offer insight into the metastatic process that only a few
clones within the primary tumor undertake, but for
which many patients are susceptible to.
Methods
Data was obtained from the TCGA study’s supplemen-
tary information where a total of 316 EOC tumors
were subjected to exome sequencing and the predicted
mutations reported [12]. We selected genes that con-
tained predicted non-silent mutations in at least 3
patients (mutated in at least ~1% of patients). These
genes were searched for enrichment in KEGG pathways
and Gene Ontologies using DAVID [13] and GeneTrail
[14]. These software packages offer robust statistical
testing with appropriate multiple-hypothesis testing
correction.
In-silico random mutagenesis was conducted using a
sequence library comprising exons that overlap with the
probes used in Agilent’s All Exon 50 MB kit. Custom
scripts were written to introduce random mutations into
these sequences and check for in-silico mutation rates in
specific pathways. We used the mutation rates observed
by the TCGA study: an AT mutation rate of 8.54 x 10-7,
1.2x10-6 for all GC bases, and 4.31 x 10-6 for CpGrepeats. Since insertion/deletions are not sequence spe-
cific, we added the rate of insertions/deletions 2.2x10-7
to the other mutation categories. 100 permutations were
conducted where each permutation consists of 316 ran-
dom mutation runs mimicking the number of tumors
analyzed by the TCGA. Data was gathered from the per-
mutations to offer an empirically observed statistic.
To determine a pathways mutational spectrum and
prevalence, each tumor’s data was queried for potentially
deleterious mutations in any genes containing a Gene
Ontology annotation of ‘Cell Adhesion’ in the ‘Molecu-
lar Function’ category. All occurrences were recorded
and summed across the pathway, for mutational
spectrum, and set of patients for pathway mutation
prevalence.
Results
Genes predicted to be mutated in at least 3 patients
resulted in a list of 1382 genes that were most significantly
enriched for Gene Ontology category “Cell Adhesion”
(Benjamini-Hochberg adjusted p-value=1.03x10-25) with
156 genes identified. This was ~2.5 times more than 60
genes expected by random permutation. In KEGG, top
enriched pathways included ‘Extracellular Matrix (ECM)-
receptor interaction’ (BH p-value=3.35x10-11) and ‘Focal
Adhesion’ (BH p-value=2.62x10-9) with 30 genes (4.5x
the expected 6.5 genes) and 45 genes (2.9x the expected
15.5 genes) respectively. Both extracellular matrix and
focal adhesion pathways share many of the same genes.
Other pathways including ‘Calcium signaling’ were signifi-
cantly enriched though less so than those mentioned
above.
To more accurately estimate the significance of the
TCGA observed mutations within the cell adhesion
genes, we carried out an in-silico random mutagenesis
simulation. If the frequency of random simulated muta-
tions in cell adhesion genes is significantly less than the
frequency of observed mutations in cell adhesion genes,
this could suggest that there is selection in the tumor
for cell adhesion mutations.
We ran 100 replicates of a trial where each trial con-
sists of 316 random mutation runs mimicking the num-
ber of tumors analyzed by the TCGA. It is important to
point out that this approach assumes equal mutational
opportunity for the entire 50 Mb capture region while
typically only a portion of the targeted region is cap-
tured. This may result in some bias of the model. Never-
theless, our results (see Figure 1a), show that the
frequency of simulated cell adhesion gene mutations in
all 100 trials is significantly less (empirical p-value less
than 0.01) than the frequency of observed cell adhesion
gene mutations. This suggests that there is indeed a
higher mutation rate in cell adhesion genes in actual
ovarian tumors.
Figure 1 Simulated and observed Extracellular matrix gene family mutations in ovarian cancer. (a) Histogram showing the ratio of
mutations in cell adhesion genes in the observed dataset (in red) and the ratio of mutations in cell adhesion genes to total mutations in
simulated mutagenesis data (in blue). (b) Mutation rates were normalized to gene numbers in the family and compared to the baseline of all
mutations in all genes. Collagens and Laminins had higher than expected mutation rates while the large gene family of Integrins had lower
mutation rates.
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enriched for mutations in the TCGA data, we deter-
mined the spectrum and the prevalence of mutations in
this functional category among all patients. Each tumor’s
data was queried for all mutations, other than those pre-
dicted to be silent, in any of the 576 genes containing a
Gene Ontology annotation of ‘Cell Adhesion’ in the
‘Molecular Function’ category. We found a broad
spectrum of mutation in this category with 366 (64%) of
genes having a potentially deleterious mutation in at
least one tumor (Table 1).
We further calculated the prevalence of ‘Cell Adhe-
sion’ mutations among all patients’ tumors. Strikingly,
281 of the 316 (89%) tumors investigated had a muta-
tion in at least one cell adhesion gene while 207 (66%)
tumors had mutations in at least two cell adhesion
genes. This number of tumors with a mutation in the
cell adhesion molecular function is comparable to the
283 automatically identified mutations in TP53. Results













KEGG ECM-receptor Interaction 1 3.35x10-11
Focal Adhesion 2 2.62x10-9
Calcium Signaling 3 2.05x10-8
Gene Ontology Cell Adhesion 1 1.03x10-25
Developmental process 14 1.03x10-15
Extracellular Matrix 19 2.56x10-14
*Enriched pathways from all genes with predicted mutations in at least 3 ovarian tu
reported here.We also observed selection of certain gene families
within functional categories that were targeted for muta-
tion while other gene families were avoided. We identi-
fied all mutations in the KEGG pathway ‘Extracellular
Matrix (ECM)-receptor interaction’ and normalized the
number of mutations to the number of genes in selected
gene families. A baseline ratio of all mutations to genes
within the KEGG pathway was subtracted from each
gene family (Figure 1b). We observed that collagens and
laminins are especially targeted for mutation having ~2
and ~1 more mutations per gene than the baseline.
Other categories including the integrins acquired fewer
mutations than the average (Figure 1b).
Conclusions
The mutational spectrum in epithelial ovarian cancer is
very narrow when only single genes are considered.
TP53 mutations are near universal [12] with few other
genes rising to significance. However, little work has














~4.5X 74% (62/84) 40% (127/316) 30
~2.9X (61%) 122/199 58% (183/316) 45
~2.9X 63% (112/179) 48% (153/316) 40
~2.5X 64% (366/576) 89% (281/316) 156
~1.5X 49% (430/869) 90% (284/316) 375
~2.8X 53% (80/150) 40% (127/316) 76
mors from the TCGA data were ranked by pvalue and selected pathways
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together, our data suggests that the spectrum of muta-
tions in cell adhesion related genes is broad across this
molecular function, with 64% of cell adhesion genes
mutated at least once, and most interestingly with 89%
of tumors observed to have at least one mutation.
The observations presented here are consistent with
several reported studies on cell adhesion and tumori-
genesis. Cell adhesion and extracellular matrix are
known to be critical pathways in the metastatic process
[15-17] and our results suggest there may be multiple
genes, within the same pathway that EOC uses to
achieve tumorogenic capability. Targeting of cell adhe-
sion related genes agrees well with multiple previous
reports of EOC specific gene expression changes in this
pathway [18,19]. However, the breadth and prevalence
of the mutational targeting of this pathway is a novel
finding. Moreover, our results confirm recent findings
that the ECM receptor interaction pathway is affected
in ovarian cancer specifically and in many other can-
cers in general. In a recent study of cancer genetic de-
regulation at the transcriptomic level, the cell adhesion
pathway was the most conserved for deregulation,
showing enrichment in 26 tumor types [20]. In the
same study, the ECM-receptor interaction pathway was
found highly deregulated in many cancers including
ovarian cancer.
The deregulation in the cell-adhesion and ECM path-
way has broad implications. Indeed a study of EOC gene
expression revealed agreement on an increase in ECM
gene expression in chemotherapy resistant tumors [21].
Moreover, molecular subtypes of tumors, based on gene
expression studies, have been identified and the categor-
ies encompassing high-grade serous EOC regularly in-
clude upregulated expression of ECM and cell adhesion
genes [22]. A recent study of CNV in EOC primary
tumors revealed an increase of extracellular matrix and
cell adhesion genes in tumors with no CCNE1 amplifica-
tion, yet with a short time to relapse [23]. Gene expres-
sion analysis of cisplatin resistant cancer cells revealed
extracellular matrix related genes as a primary differenti-
ator of chemotherapy resistance and Collagen 6A3
(COL6A3) has been shown to contribute to cisplatin re-
sistance [24]. Our analysis agrees well with previous
findings by Capo-chichi and colleagues that collagen IV
and laminin are aberrantly expressed in primary ovarian
tumors [25].
The importance of extracellular matrix and cell adhe-
sion genes in EOC and other cancers is clear [26,27].
Other groups’ gene expression studies, and our own ana-
lysis of both the prevalence and broad spectrum of mu-
tation within cell adhesion gene groups reinforce the
likely central role cell adhesion plays in epithelial ovarian
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